| Vision Disorder (usually involving brief light trails, flashes or image persistence occurring at the edges of the visual field. Most commonly, these occur in association with light adaptation) |
62% |
|
Gastrointestinal Disorders
|
|
| Nausea |
53% |
| Diarrhea |
43% |
| Vomiting |
40% |
| Constipation |
27% |
| Decreased Appetite |
19% |
| Esophageal Disorders |
11% |
|
General Disorders
|
|
| Edema |
28% |
| Fatigue |
20% |
|
Other
|
|
| Dizziness |
16% |
| Neuropathy |
13% |
| Dysgeusia |
12% |
| Rash |
10% |
|
Investigations
|
|
| Alanine Aminotransferase Increased |
13% |
|
|
Severe (grade 3 or 4) treatment related adverse events (all <1%-5% of cases)
|
|
| Stomatitis |
| Constipation |
| Fatigue |
| Dyspnea |
| Neuropathy |
| Pneumonitis |
| Aspartate Aminotransferase Increased |
| Alanine Aminotransferase Increased |
| Neutropenia |
| Lymphopenia |
| Hypophosphatemia |
|
|
Additional recently described common and/or characteristic side effects
|
|
| Renal cysts (rare) |
| Asymptomatic bradycardia (frequency unknown) |
| Rapid onset low testosterone in men (common) |
